新股首日 | 思派健康漲超27%
思派健康(00314)首掛上市,公告顯示,公司發行991.94萬股股份,每股定價18.6港元,每手200股,所得款項淨額約1.204億港元。截至發稿,漲27%,報23.8港元,成交額2600萬港元。
據悉,按2021年的收入計算,思派健康的特藥藥房業務經營着最大的私營特藥藥房,而該公司的醫生研究協助經營着最大的腫瘤現場管理組織。截至2022年6月30日,思派健康的健康保險服務通過連接中國150多個主要城市的醫院、全科醫生及專家的健康服務提供商網絡服務約23.9百萬名加入健康保險計劃的會員。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.